©The Author(s) 2026.
World J Gastroenterol. Jan 14, 2026; 32(2): 114057
Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.114057
Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.114057
Figure 7 Cedrol ameliorated dextran sulfate sodium-induced gut microbiota dysbiosis.
A: Venn diagram of amplicon sequence variants for each group; B and C: Alpha diversity analysis (Shannon and Simpson indices); D and E: Beta diversity was displayed via principal coordinates analysis and non-metric multidimensional scaling based on weighted UniFrac algorithm; F: Phylum-level abundance distribution; G: Genus-level relative abundance; H: Differences in bacterial abundance were analyzed at the genus level across various groups (P < 0.05); I: Linear discriminate analysis effect size-derived linear discriminant analysis scores; J: Kyoto Encyclopedia of Genes and Genomes functional prediction heatmap. Data are expressed as mean ± SD (n = 4). CE: Cedrol; DSS: Dextran sulfate sodium; PCoA: Principal co-ordinates analysis; NMDS: Non-metric multidimensional scaling; LDA: Linear discriminate analysis; KEGG: Kyoto Encyclopedia of Genes and Genomes.
- Citation: Zhao YQ, Zhang Y, Qin Y, Zhang RY, Wang JP. Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation. World J Gastroenterol 2026; 32(2): 114057
- URL: https://www.wjgnet.com/1007-9327/full/v32/i2/114057.htm
- DOI: https://dx.doi.org/10.3748/wjg.v32.i2.114057